Healthcare Utilization and Costs for Huntington Disease Patients Prescribed Tetrabenazine

被引：0
|
作者：
Anderson, Karen E. [1 ]
Iyer, Ravi [2 ]
Gandhi, Sanjay [2 ]
Abler, Victor [2 ]
Davis, Brian [3 ]
Irwin, Debra [3 ]
Sung, Victor [4 ]
机构：
[1] Georgetown Univ Hosp, Washington, DC 20007 USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Truven Hlth Analyt, Cambridge, MA USA
[4] Univ Alabama, Birmingham, AL USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.044
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany
    Canbay, Ali
    Kachru, Nandita
    Haas, Jennifer Scarlet
    Meise, Dominic
    Ozbay, A. Burak
    Sowa, Jan-Peter
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [42] Healthcare resource utilisation and costs among patients with versus without Huntington's disease in the US population
    Exuzides, A.
    To, T. M.
    Abbass, I.
    Surinach, A.
    Fuller, R.
    Luo, J.
    MOVEMENT DISORDERS, 2020, 35 : S97 - S97
  • [43] Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
    Reynolds, Shannon L.
    Ghate, Sameer R.
    Sheer, Richard
    Gandhi, Pranav K.
    Moretz, Chad
    Wang, Cheng
    Sander, Stephen
    Costantino, Mary E.
    Annavarapu, Srinivas
    Andrews, George
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2017, 15
  • [44] Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
    Shannon L. Reynolds
    Sameer R. Ghate
    Richard Sheer
    Pranav K. Gandhi
    Chad Moretz
    Cheng Wang
    Stephen Sander
    Mary E. Costantino
    Srinivas Annavarapu
    George Andrews
    Health and Quality of Life Outcomes, 15
  • [45] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH CERVICAL DYSTONIA
    Hull, M.
    Anupindi, R.
    He, J.
    Danchenko, N.
    DeKoven, M.
    Bouchard, J.
    VALUE IN HEALTH, 2022, 25 (01) : S106 - S106
  • [46] Healthcare utilization and costs of patients with rosacea in an insured population
    Romanowicz, Michael
    Stephenson, Judith J.
    Del Rosso, James Q.
    Lenhart, Greg
    JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (01) : 41 - 49
  • [47] Impact of tetrabenazine on balance and gait in individuals with Huntington's disease
    Kegelmeyer, D.
    Fritz, N.
    Kloos, A.
    Kostyk, S.
    NEUROTHERAPEUTICS, 2013, 10 (01) : 171 - 172
  • [48] Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
    Marshall, FJ
    Walker, F
    Frank, S
    Oakes, D
    Plumb, S
    Factor, SA
    Fahn, S
    Hunt, VP
    Jankovic, J
    Shinaman, A
    Shoulson, I
    Goldstein, J
    Corey-Bloom, J
    Belden, J
    Wojcieszek, J
    Nickerson, C
    Higgins, D
    McCall, M
    Sanchez-Ramos, J
    Stepanov, N
    Kostyk, S
    Harrison, J
    Testa, C
    Shannon, B
    Feigin, A
    Radtke, D
    Nance, M
    Stanton, P
    Ashizawa, T
    Hunter, C
    Ondo, W
    Rose, K
    Geschwind, M
    Jaglin, J
    Shannon, K
    Matthews, M
    Colcher, A
    Riendl, P
    Blindauer, K
    Dustin, K
    Anderson, K
    Fowler, S
    Mehta, D
    Hanna, P
    Lindsay, P
    Eberly, S
    Zhao, HW
    MacDonald, M
    Young, A
    NEUROLOGY, 2006, 66 (03) : 366 - 372
  • [49] HEALTHCARE RESOURCE UTILIZATION AND ACUTE COSTS IN FRENCH PATIENTS WITH CORONARY ARTERY DISEASE AND PERIPHERAL ARTERY DISEASE
    Emery, C.
    Torreton, E.
    Oksen, D.
    Briere, J. B.
    Evers, T.
    Fagnani, F.
    VALUE IN HEALTH, 2019, 22 : S126 - S126
  • [50] The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
    Fasano, Alfonso
    Cadeddu, Federica
    Guidubaldi, Arianna
    Piano, Carla
    Soleti, Francesco
    Zinzi, Paola
    Bentivoglio, Anna Rita
    CLINICAL NEUROPHARMACOLOGY, 2008, 31 (06) : 313 - 318
12345